lunes, 6 de mayo de 2024

FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer

https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-enhertu-her2-positive-solid-tumors?cid=eb_govdel

No hay comentarios:

Publicar un comentario